Similar articles

• Mechanism of immune escape of cancer and its regulation.

  Morita R, Hirohashi Y, Torigoe T. Morita R, et al. Rinsho Ketsueki. 2009 May;50(5):375-80. Rinsho Ketsueki. 2009. PMID: 19483397 Review. No abstract available.
• [Tumor specific antigen and cytotoxic T lymphocytes].

  Uenaka A, Nakayama E. Uenaka A, et al. Nihon Rinsho. 2005 Apr;63 Suppl 4:568-73. Nihon Rinsho. 2005. PMID: 15861712 Review. Japanese. No abstract available.
• HLA class I - associated immunodominance affects CTL responsiveness to an ESO recombinant protein tumor antigen vaccine.

  Bioley G, Guillaume P, Luescher I, Yeh A, Dupont B, Bhardwaj N, Mears G, Old LJ, Valmori D, Ayyoub M. Bioley G, et al. Clin Cancer Res. 2009 Jan 1;15(1):299-306. doi: 10.1158/1078-0432.CCR-08-1747. Clin Cancer Res. 2009. PMID: 19118058
• Immunotherapy: natural versus synthetic peptides.

  Protti MP, Bellone M. Protti MP, et al. Immunol Today. 1998 Feb;19(2):98. Immunol Today. 1998. PMID: 9509766 No abstract available.
• HLA-A3 restricted mutant ras specific cytotoxic T-lymphocytes induced by vaccination with T-helper epitopes.

  Gjertsen MK, Saeterdal I, Saebøe-Larssen S, Gaudernack G. Gjertsen MK, et al. J Mol Med (Berl). 2003 Jan;81(1):43-50. doi: 10.1007/s00109-002-0390-y. Epub 2002 Nov 13. J Mol Med (Berl). 2003. PMID: 12545248